Beijing Hotgen Biotech Hits Day Low of CNY 125.16 Amid Price Pressure

Beijing Hotgen Biotech Co., a large-cap player in the Pharmaceuticals & Biotechnology sector, experienced a significant decline today, with its stock price dropping by 5.47%. The stock reached an intraday low of CNY 125.16, reflecting ongoing challenges within the company. Over the past week, Beijing Hotgen has seen a 7.42% decrease, and its performance over the last month has been even more pronounced, with a decline of 14.13%. Year-to-date, the stock has fallen by 21.85%, contrasting sharply with the China Shanghai Composite, which has gained 2.85% during the same period. Despite a remarkable 120.87% increase over the past year, the company has faced persistent difficulties, reporting negative results for the last 12 consecutive quarters. Key financial metrics indicate a troubling trend, with net sales declining by 4.41% and a net profit of CNY -75.78 million reflecting a significant drop of 58.81%. The company's return on equity stands at -7.31%, further highlighting its current financial struggles.